Daniel Anderson, Robert Langer, and their former postdoc Omid Veiseh launched Duracyte, a biotechnology company that produces implantable "living drug factories" that replace repeated injections and infusions with continuous, self-adjusting dosing. Duracyte plans to begin clinical trials for recurrent ovarian cancer later this year.